The firms reported promising data from two trials of zipalertinib in patients who have received prior EGFR exon 20-directed therapy and those who haven't.
Black Diamond's silevertinib aims to challenge Tagrisso, offering broad EGFR mutation coverage, as key trial results are ...
CURE spoke with Dr. Xiuning Le during the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer. Lung cancer research has recognized the role of EGFR ...
Hypoxia, or low oxygen in the body, is common in solid tumors. Now, researchers have identified that an RNA molecule, EUDAL, ...
ZEGFROVY: Targeting EGFR exon20ins and a wide spectrum of EGFR mutations The latest data from the multinational ... With a median follow-up of 15.2 months, the median duration of response (DoR) was 19 ...
Never-smoker Leah Phillips, co-founder of the Young Lung Cancer Initiative, raises awareness that anyone with lungs can develop lung cancer. Leah Phillips, co-founder of the Young Lung Cancer ...
An Overland Park man is riding 700 miles on his bike to raise money for cancer research after he was diagnosed with lung cancer.
Zacks Investment Research on MSN
Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug?
Black Diamond Therapeutics, Inc. (BDTX) is developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company’s lead pipeline candidate is silevertinib.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best NASDAQ Stocks to Buy with Huge Upside Potential. On September 9, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced five-year ...
AstraZeneca (($AZN)) announced an update on their ongoing clinical study. Study Overview: AstraZeneca is conducting a Phase I/IIa study titled A ...
The approval applies to patients with locally advanced or metastatic non-small cell lung cancer with ROS1 gene fusion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback